Authors respond to letter on SGLT2 versus GLP-1 agonist psoriatic arthritis study

The wire

1. 01Yen and colleagues published a response to a letter questioning how findings from their emulated target trial comparing SGLT2 inhibitors with GLP-1 receptor agonists in psoriatic arthritis should be read.
2. 02Relevant to clinicians weighing incretin therapy in patients with inflammatory arthritis, where comparative evidence rests on observational database analyses.
3. 03This is journal correspondence rather than new data; the underlying comparison remains an emulated trial from existing records, not a randomised study.

From the source

Findings Interpretation Concerns Regarding the Emulated Target Trial of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Psoriatic Arthritis [Response to Letter]

Drug design, development and therapy · 2026 · Yen FS, Wang SI, Hwu CM et al.